The Phase 2 study in patients with C9orf72 -related ALS/FTD was a multi-center, randomized, double-blind, placebo-controlled parallel-group, two-arm study with an open-label treatment period.
The partnership addresses a critical market failure: 51 million Americans need behavioral health services but face barriers due to fragmented systems, inaccurate provider data, and opaque pricing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results